FDA Pulls Evusheld EUA; Former Adviser Urges EUA For Veru’s Drug

By Beth Wang / January 26, 2023 at 5:14 PM
Story Updated FDA on Thursday (Jan. 26) announced AstraZeneca’s coronavirus drug Evusheld (tixagevimab co-packaged with cilgavimab) is no longer authorized for use , pending further notice, coming as the agency faces pressure from a former adviser to authorize another COVID-19 drug, Veru’s proposed sabizabulin, which an FDA advisory committee narrowly recommended not be authorized last November. Evusheld is longer authorized for emergency use in the United States, as data show the drug is unlikely to be active...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.